Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025

Description

Nucleic acid and gene therapies for neuromuscular disorders are innovative treatments designed to correct or compensate for genetic mutations that cause these conditions. Neuromuscular disorders (NMDs) affect the muscles and nerves, often due to inherited mutations. These therapies utilize nucleic acids or genetic material to repair, replace, or modulate gene expression, addressing the underlying cause of the disorder.

The primary disorders targeted by these therapies include motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies such as muscular dystrophies. Motor neuron diseases are a group of progressive neurological conditions that impact motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. Treatment approaches include adeno-associated virus (AAV) gene therapy, postnatal gene therapy, and therapies for spinal muscular atrophy. These therapies are applied in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgery centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides nucleic acid and gene therapies in neuromuscular disorders market statistics, including nucleic acid and gene therapies in neuromuscular disorders industry global market size, regional shares, competitors with a nucleic acid and gene therapies in neuromuscular disorders market share, detailed nucleic acid and gene therapies in neuromuscular disorders market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. This nucleic acid and gene therapies in neuromuscular disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $6.84 billion in 2024 to $7.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increase in regulatory approvals, demand for nucleic acid therapeutics, demand for more precise and effective therapies, demand for effective gene therapies, and increase in the number of gene therapy-based discoveries.

The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing investments in research and development, growing demand for precision medicine, rising approval of gene therapy products, and increasing prevalence of chronic disorders. Major trends in the forecast period include advances in patient care, high performance chromatography, innovative solutions for conditions, advancements in gene editing technologies, and availability of nucleic acid extraction technology.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical innovation by increasing costs for Adeno-associated virus vector-based therapies and Clustered regularly interspaced short palindromic repeats -Cas9 components imported from Switzerland and South Korea, potentially raising specialty pharmacy costs and postponing rare disease treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of genetic disorders is expected to drive the growth of the nucleic acid and gene therapies in the neuromuscular disorders market. Genetic disorders arise from abnormalities in an individual's DNA, either inherited or resulting from mutations. The rise in these disorders is attributed to factors such as genetic mutations, environmental influences, lifestyle changes, and advancements in diagnostic technologies. Nucleic acid and gene therapies play a crucial role in addressing genetic neuromuscular disorders by correcting or replacing defective genes to restore normal function. For example, in May 2024, according to Cure SMA, a US-based non-profit organization, approximately 9,000 to 9,500 individuals in the United States are currently living with Spinal Muscular Atrophy (SMA), with Type 2 SMA accounting for 37% of cases. The estimated incidence rate of SMA is approximately 1 in 15,000 births. As a result, the growing prevalence of genetic disorders is fueling the demand for nucleic acid and gene therapies in the neuromuscular disorders market.

Leading companies in the market are advancing gene therapy solutions to directly target the root causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy involves modifying or repairing genetic material within a patient's cells to address defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years. Elevidys is administered as a single intravenous infusion, offering a simplified alternative to ongoing infusion-based therapies. This therapy delivers a gene encoding a shortened form of dystrophin, known as micro-dystrophin, which is crucial for muscle function. By enabling muscle cells to produce a functional dystrophin protein, Elevidys aims to slow or potentially reverse disease progression.

In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. This acquisition aims to strengthen Novartis' gene therapy portfolio for inherited neuromuscular diseases. By integrating Kate Therapeutics' AAV-based gene therapy platform DELIVER and its preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1, Novartis is expanding its capabilities in developing targeted therapies for genetic muscle and heart diseases. Kate Therapeutics Inc. is a US-based biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for genetically defined neuromuscular conditions.

Major players in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Genethon S.A, Axovant Gene Therapies Inc .

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in nucleic acid and gene therapies in neuromuscular disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nucleic acid and gene therapies in neuromuscular disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nucleic acid and gene therapies in neuromuscular disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid and gene therapies in neuromuscular disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Sanofi S.A; Novartis AG; Eli Lilly and Company; Astellas Pharma Inc; Biogen Inc; Vertex Pharmaceuticals Inc; BioMarin Pharmaceuticals Inc; Nippon Shinyaku Co Ltd; Sarepta Therapeutics Inc; Ionis Pharmaceuticals, Inc.; Ultragenyx Pharmaceutical Inc; Amicus Therapeutics Inc; Arrowhead Pharmaceuticals Inc; Regenxbio Inc; UniQure N.V.; Genethon S.A; Axovant Gene Therapies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34099u

1. Executive Summary

2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Characteristics

3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends And Strategies

4. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Growth Analysis And Strategic Analysis Framework

5.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Rate Analysis
5.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Total Addressable Market (TAM)

6. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation

6.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Motor Neuron Diseases
Neuropathies
Neuromuscular Junction Disorders
Myopathies Including Muscular Dystrophies
6.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adeno-Associated Viruses Gene Therapy
Postnatal Gene Therapy
Spinal Muscular Atrophy
6.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
6.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amyotrophic Lateral Sclerosis (ALS)
Spinal Muscular Atrophy (SMA)
Primary Lateral Sclerosis (PLS)
6.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Charcot-Marie-Tooth Disease (CMT)
Hereditary Sensory and Autonomic Neuropathy (HSAN)
Peripheral Neuropathies
6.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Myasthenia Gravis
Lambert-Eaton Myasthenic Syndrome (LEMS)

7. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regional And Country Analysis

7.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

8.1. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

9.1. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
9.2. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

10.1. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

11.1. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
11.2. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

12.1. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

13.1. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

14.1. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
14.2. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

15.1. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
15.2. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

16.1. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

17.1. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

18.1. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

19.1. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

20.1. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

21.1. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
21.2. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

22.1. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

23.1. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
23.2. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

24.1. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
24.2. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

25.1. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
25.2. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

26.1. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
26.2. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

27.1. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

28.1. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
28.2. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

29.1. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
29.2. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Company Profiles

30.1. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape
30.2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Other Major And Innovative Companies

31.1. Eli Lilly and Company
31.2. Astellas Pharma Inc
31.3. Biogen Inc
31.4. Vertex Pharmaceuticals Inc
31.5. BioMarin Pharmaceuticals Inc
31.6. Nippon Shinyaku Co Ltd
31.7. Sarepta Therapeutics Inc
31.8. Ionis Pharmaceuticals, Inc.
31.9. Ultragenyx Pharmaceutical Inc
31.10. Amicus Therapeutics Inc
31.11. Arrowhead Pharmaceuticals Inc
31.12. Regenxbio Inc
31.13. UniQure N.V.
31.14. Genethon S.A
31.15. Axovant Gene Therapies, Inc

32. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

34. Recent Developments In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

35. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market High Potential Countries, Segments and Strategies

35.1 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Countries Offering Most New Opportunities
35.2 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Segments Offering Most New Opportunities
35.3 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer